Aarti Drugs Reports Strong Profit Growth Amid Rising Debt Concerns

Aarti Drugs, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects notable shifts in its financial metrics. The company's performance for the quarter ending September 2025 has shown a significant uptick, with a reported profit after tax (PAT) of Rs 99.19 crore, marking a growth of 45.33% over the last six months. This positive trend is further supported by an operating profit to interest ratio, which stands at a robust 10.95 times, indicating strong operational efficiency.
Additionally, Aarti Drugs has reported cash and cash equivalents of Rs 95.70 crore, the highest recorded in the first half of the year. These figures contribute to a favorable assessment of the company's financial health. However, it is important to note that the debt-equity ratio has reached 2.22 times, which may warrant attention as it reflects the company's leverage position.

In terms of market performance, Aarti Drugs has delivered a return of 5.80% over the past year, outperforming the Sensex, which returned 5.09% in the same period. The stock's recent evaluation adjustment underscores the evolving dynamics within the company and its market environment.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.